Skip to content
HowShorted

Teladoc Health, Inc. short interest in 2023

In 2023, Teladoc Health, Inc.'s disclosed short interest ran from 18.32% of shares outstanding on 13 Jan 2023 to 11.73% on 29 Dec 2023, a change of -6.59 percentage points. The year's high was 18.32% on 13 Jan 2023 and its low 11.35% on 30 Nov 2023, averaging 15.40% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.15 days on 14 Apr 2023. Full history: Teladoc Health, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Teladoc Health, Inc. in 2023

2023 in figures

Start of year
18.32% (13 Jan 2023)
End of year
11.73% (29 Dec 2023)
Change
-6.59 pp
High
18.32% (13 Jan 2023)
Low
11.35% (30 Nov 2023)
Average
15.40%
Highest days to cover
11.15 (14 Apr 2023)
SEC filings marked
9

Every report in 2023

Teladoc Health, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202318.32%6.24results (8-K)
31 Jan 202317.09%6.66
15 Feb 202317.22%7.13
28 Feb 202315.54%4.09results (8-K)
15 Mar 202315.87%7.1410-K filed
31 Mar 202316.56%8.98
14 Apr 202316.03%11.15
28 Apr 202316.43%4.08results (8-K)
15 May 202316.15%9.0810-Q filed
31 May 202316.02%8.18
15 Jun 202315.48%6.86
30 Jun 202315.50%7.42
14 Jul 202316.07%5.09
31 Jul 202316.86%2.50results (8-K), 10-Q filed
15 Aug 202316.83%5.59
31 Aug 202317.74%8.04
15 Sep 202316.53%7.66
29 Sep 202315.33%5.00
13 Oct 202314.68%4.84
31 Oct 202312.64%3.41results (8-K), 10-Q filed
15 Nov 202311.39%4.02
30 Nov 202311.35%4.38
15 Dec 202312.32%4.09
29 Dec 202311.73%5.19

See also: Teladoc Health, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.